Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002383 | 1.00 | GABRA1 (0.34) | GABRA1GABRB1SMN1; SMN2PTGDR2MAOB | |
| SCHEMBL29366609 | 0.81 | NOTUM (0.40) | SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL26045754 | 0.81 | NOTUM (0.40) | SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL15197100 | 0.80 | DGAT1 (0.42) | SMN1; SMN2PTGDR2MAOBMAOAALDH1A1 | |
| SCHEMBL23087740 | 0.76 | HDAC1 (0.41) | SMN1; SMN2PTGDR2MAOBMAOAALDH1A1 | |
| SCHEMBL25994225 | 0.75 | SMN1; SMN2 (0.40) | SMN1; SMN2PTGDR2MAOBMAOAALDH1A1 | |
| SCHEMBL23087599 | 0.73 | ALDH1A1 (0.42) | SMN1; SMN2PTGDR2MAOBMAOAALDH1A1 | |
| SCHEMBL19126014 | 0.73 | HPGD (0.41) | SMN1; SMN2PTGDR2MAOBMAOAALDH1A1 | |
| SCHEMBL27002510 | 0.72 | GPR35 (0.36) | GABRA1GABRB1 | |
| SCHEMBL29915097 | 0.72 | GPR35 (0.36) | GABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192745-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | GABRA1 4454/4885GABRB1 3802/4885SMN1; SMN2 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.